Syros Pharmaceuticals’ Shareholders Approve Key Updates and Elections
Company Announcements

Syros Pharmaceuticals’ Shareholders Approve Key Updates and Elections

The latest update is out from Syros Pharmaceuticals (SYRS).

At Syros Pharmaceuticals’ 2024 Annual Meeting, stockholders greenlit a significant amendment to the Equity Incentive Plan, adding 1,750,000 shares for issuance. Additionally, they voted for the election of three Class II directors and passed several other key proposals, including a substantial increase in authorized capital stock and an update to incorporate new Delaware law provisions for officer exculpation. Shareholders also ratified the appointment of Ernst & Young LLP as the auditor for the upcoming fiscal year and endorsed the executive officers’ compensation on an advisory basis.

Learn more about SYRS stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlySyros Pharmaceuticals trading resumes
TheFlySyros Pharmaceuticals says SELECT-MDS-1 trial did not meet primary endpoint
TheFlySyros Pharmaceuticals trading halted, news pending
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App